Product image of Icatibant Fresenius (Icatibant Acetate) supplied by GNH India

Icatibant Fresenius

Active Ingredient:
Icatibant Acetate
Origin:
EU

Icatibant Fresenius (Icatibant Acetate)

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is employed to treat acute attacks of hereditary angioedema in affected individuals.

GNH India supplies Icatibant Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Manufacturer / TM Owner

Fresenius Kabi Norge As

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Icatibant Fresenius is used to manage hereditary angioedema by blocking the bradykinin pathway.
  • Hereditary angioedema (HAE) attacks: provides rapid relief of swelling and associated pain.
  • HAE type I: reduces the severity and duration of acute episodes.
  • HAE type II: mitigates bradykinin‑mediated vascular permeability during attacks.

How It Works

  • Icatibant acetate selectively antagonizes the bradykinin B2 receptor on endothelial cells, preventing bradykinin from binding and triggering vasodilation and increased vascular permeability. By blocking this receptor, the drug curtails the cascade that leads to fluid extravasation and tissue swelling characteristic of hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Erythema: localized redness around the injection area.
  • Swelling: transient edema at the site of administration.
  • Nausea: occasional feeling of queasiness.
  • Headache: mild to moderate head pain.
  • Dizziness: transient light‑headed sensation.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Angioedema: unexpected swelling of the face, lips, or airway.
  • Severe hypotension: marked drop in blood pressure.
  • Urticaria: widespread hives.
  • Thrombocytopenia: low platelet count.
  • Severe allergic reaction: systemic hypersensitivity requiring discontinuation.

Precautions & Warnings

  • When prescribing Icatibant Fresenius, clinicians should consider several safety precautions.
  • Pregnancy: consult a healthcare provider; safety not established.
  • Breastfeeding: caution advised; excretion in milk is unknown.
  • Renal impairment: monitor patients; no specific dosage adjustment known.
  • Concomitant ACE inhibitors: may increase risk of angioedema.
  • Hypersensitivity: discontinue if a severe allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medications that influence the bradykinin system or cardiovascular function.

Major Interactions (Avoid)

  • ACE inhibitors: increased risk of angioedema.
  • Angiotensin receptor blockers: may potentiate bradykinin‑mediated effects.

Moderate Interactions (Monitor Closely)

  • Diuretics: possible additive blood‑pressure effects.
  • Other bradykinin‑modulating agents: additive risk of swelling.
  • NSAIDs: may heighten hypersensitivity reactions.

Frequently Asked Questions

Icatibant Fresenius is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients who experience swelling episodes caused by excess bradykinin. It helps to rapidly reduce swelling and associated discomfort.

Icatibant acetate works by selectively blocking the bradykinin B2 receptor on blood‑vessel walls. This prevents bradykinin from causing vasodilation and increased vascular permeability, thereby limiting the swelling that characterises HAE attacks.

The dosage of Icatibant Fresenius is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. The prescriber will specify the exact amount and frequency for each individual case.

Safety data for icatibant acetate in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks and discuss these considerations with the patient before use.

To request Icatibant Fresenius, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other HAE therapies such as C1‑esterase inhibitor concentrates replace the deficient protein. Icatibant directly blocks the downstream mediator bradykinin, offering a rapid, subcutaneous option that does not require intravenous administration.

Icatibant Fresenius should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

The medication is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver.

Serious risks include anaphylaxis, severe angioedema, and profound hypotension. Patients should be monitored for signs of allergic reaction or rapid swelling, especially after the first dose, and seek immediate medical attention if these occur.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant acetate or any of the formulation components. Caution is also advised for patients with a history of severe allergic reactions or uncontrolled cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant Acetate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT